Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rituximab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    843 result(s) found for: Rituximab. Displaying page 1 of 43.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-001117-86 Sponsor Protocol Number: 16/0340 Start Date*: 2017-07-25
    Sponsor Name:University College London
    Full Title: A phase IV, prospective, randomised single-blind UK multicentre non-inferiority trial of low-dose versus standard dose rituximab for prevention of relapses in acquired TTP
    Medical condition: Acquired thrombotic thrombocytopenic purpura
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-004977-12 Sponsor Protocol Number: MO19872 Start Date*: 2006-06-22
    Sponsor Name:F. Hoffmann-La Roche Limited
    Full Title: A Phase IIIb study of MabThera® (rituximab) maintenance therapy in patients with follicular Non-Hodgkin’s Lymphoma who have responded to induction therapy.
    Medical condition: Follicular non Hodgkin's Lymphoma (NHL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FI (Completed) SE (Completed) SK (Completed) IT (Completed) GR (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-000484-23 Sponsor Protocol Number: NEFRTX1 Start Date*: 2020-07-09
    Sponsor Name:Vall d'Hebron Institute of Research
    Full Title: CHARACTERIZATION OF RITUXIMAB PHARMACOKINETICS IN PATIENTS WITH KIDNEY DISEASES WITH PRIMARY GLOMERULAR AFFECTATION
    Medical condition: KIDNEY DISEASES WITH PRIMARY GLOMERULAR AFFECTATION (glomerulonefritis membranosa, glomerulonefritis por cambios mínimos, vasculitis, glomerulosclerosis focal y segmentaria.)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-000647-12 Sponsor Protocol Number: ML28881 Start Date*: 2013-06-09
    Sponsor Name:ROCHE S.p.A.
    Full Title: A single arm, multicentre, phase IIIb study to evaluate safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab administered during induction phase or maintenance in previously u...
    Medical condition: CD20+ diffuse large B-cell lymphoma or CD20+ follicular non-Hodgkin’s lymphoma grade 1, 2 or 3a
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000721-31 Sponsor Protocol Number: RIDOSE-MS Start Date*: 2018-07-04
    Sponsor Name:Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital
    Full Title: RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MS A randomized trial of long-term dosage of rituximab in multiple sclerosis The RIDOSE-MS trial is a multi-centre trial of long-term ...
    Medical condition: Patients with multiple sclerosis (MS), 20 - 52 years of age, that have completed the RIFUND-MS trial (EudraCT 2015-004116-38) will be offered to continue in this extension trial, RODOSE-MS. In addi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021377-36 Sponsor Protocol Number: BO22334 Start Date*: 2010-11-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: “Estudio de fase III en dos etapas, abierto, internacional, multicéntrico, aleatorizado y controlado para investigar la farmacocinética, la eficacia y la seguridad de rituximab s.c. conjuntamente c...
    Medical condition: Linfoma Folicular (LF) CD-20 psoitivo grado 1-2, 3a sin tratar previamente Previously untreated, CD20-positive follicular lymphoma (FL) grade 1-2, 3a
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061170 Follicle centre lymphoma, follicular grade I, II, III LLT
    12.1 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) BE (Completed) SK (Completed) IT (Completed) DK (Completed) DE (Completed) FR (Completed) FI (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-005640-81 Sponsor Protocol Number: RR06/7719 Start Date*: 2007-09-04
    Sponsor Name:University of Leeds
    Full Title: A PLACEBO CONTROLLED STUDY OF THE EFFECT OF EXTENDED TREATMENT WITH RITUXIMAB ON RESISTANT RHEUMATOID ARTHRITIS:
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018780-42 Sponsor Protocol Number: OMB113676 Start Date*: 2010-10-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
    Medical condition: Indolent B-Cell Non-Hodgkin's Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Prematurely Ended) BG (Prematurely Ended) BE (Completed) FR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-002810-37 Sponsor Protocol Number: RI-01-007 Start Date*: 2020-03-09
    Sponsor Name:Dr. Reddy’s Laboratories S.A.
    Full Title: A Randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continu...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) LT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-001807-29 Sponsor Protocol Number: 1508058 Start Date*: 2015-06-09
    Sponsor Name:CHU de Saint-Etienne
    Full Title: Pharmacokinetic study of rituximab induction regimen in ANCA-associated vasculitis : a predictive factor of clinical outcome? (MONITUX) - A multicentric study
    Medical condition: Granulomatosis with polyangiitis Microscopic polyangiitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10047065 - Vascular disorders 10072579 Granulomatosis with polyangiitis PT
    18.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001569-33 Sponsor Protocol Number: LLC-R-FCM-1 Start Date*: 2005-09-23
    Sponsor Name:Dept. Hematology, Hospital Clinic
    Full Title: First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia. Tratamie...
    Medical condition: Patients diagnosed with chronic lymphocytic leukemia (CLL) according to the WHO guidelines, within 18 and 71 years and not previously treated
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002103-32 Sponsor Protocol Number: 50-03B Start Date*: 2005-03-02
    Sponsor Name:GELA-Recherche Clinique
    Full Title: Phase III multicentre open-label randomised study of ICE plus Rituximab (R-ICE) versus DHAP plus Rituximab (R-DHAP) in previously treated patients with CD 20 positive diffuse large B-cell lymphoma,...
    Medical condition: CD 20 positive diffuse large B cell lymphoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006001-10 Sponsor Protocol Number: RTX500/1000 Start Date*: 2012-03-19
    Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA
    Full Title: Efficacy of rituximab at the dose of 500 mg e.v., two infusions two weeks apart, versus rituximab at the usual dose of 1000 mg, two infusions two weeks apart, in patients affected by rheumatoid art...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003610-15 Sponsor Protocol Number: RITUXVAS Start Date*: 2005-12-15
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: An international, randomised, open trial comparing a rituximab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of 'generalised' ANCA associated vasculitis.
    Medical condition: Anti neutophil cytoplasmic antibody (ANCA) associated vasculitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003230-17 Sponsor Protocol Number: MO28457 Start Date*: 2013-02-14
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE PATIENT PREFERENCE WITH SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CD20+ DI...
    Medical condition: The target population will consist of adults with previously untreated CD20+ DLBCL or CD20+ follicular NHL Grade 1, 2 or 3a, according to the WHO classification system.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) NL (Completed) IT (Completed) PT (Completed) SE (Completed) AT (Completed) DK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003893-29 Sponsor Protocol Number: BAY80-6946/17067 Start Date*: 2015-06-25
    Sponsor Name:Bayer AG
    Full Title: A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’...
    Medical condition: Patients with relapsed indolent B-cell non-Hodgkin's lymphoma
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) PT (Completed) DE (Prematurely Ended) ES (Prematurely Ended) BE (Completed) LT (Completed) HU (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) BG (Prematurely Ended) LU (Completed) GR (Completed) SK (Prematurely Ended) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-018266-35 Sponsor Protocol Number: I08013 Start Date*: 2010-08-11
    Sponsor Name:CHU de LIMOGES
    Full Title: Efficacité du Rituximab au cours du syndrome néphrotique idiopathique ciclosporinodépendant de l'enfant.
    Medical condition: syndrome néphrotique ciclosporinodépendant de l'enfant
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029164 Nephrotic syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005269-37 Sponsor Protocol Number: 836021009 Start Date*: 2014-10-02
    Sponsor Name:St. Antonius Hospital
    Full Title: RITUXIMAB IN LIFE THREATENING THERAPY RESISTANT PROGRESSIVE INTERSTITIAL PNEUMONITIS
    Medical condition: Patients with rare Immune mediated inflammatory diseases (IMIDs) involving the lungs causing interstitial pneumonitis (IP).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000624-28 Sponsor Protocol Number: OFA2 Start Date*: Information not available in EudraCT
    Sponsor Name:IRCCS ISTITUTO GIANNINA GASLINI
    Full Title: Ofatumumab versus Rituximab in children with steroid and calcineurin inhibitor-dependent idiopatic nephrotic syndrome: an open-label, randomized, controlled, superiority trial.
    Medical condition: steroid and calcineurin inhibitor-dependent idiopatic nephrotic syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10029164 Nephrotic syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004864-81 Sponsor Protocol Number: ORION Start Date*: 2021-12-17
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: Proposta di studio per valutare l’efficacia di Obinutuzumab, un anticorpo anti-CD20, in pazienti con nefropatia membranosa intolleranti, resistenti o dipendenti alla terapia con Rituximab (studio O...
    Medical condition: PRIMARY MEMBRANOUS NEPHROPATHY
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 20:02:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA